Vitamin D repletion and prevention of bone loss in nonosteoporotic women with breast cancer.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 9026-9026
Author(s):  
S. Servitja ◽  
D. Prieto-Alhambra ◽  
M. Martinez-Garcia ◽  
L. Garrigos ◽  
M. J. Pena ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Bone Loss ◽  
Prevention Of Bone Loss

Low Vitamin D Tied to Bone Loss in Breast Cancer

2006 ◽  
Vol 39 (15) ◽  
pp. 29
Author(s):  
JANE SALODOF MACNEIL
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
Bone Loss

scholarly journals Bisphosphonates and the prevention of osteoporosis in the adjuvant setting

2005 ◽  
Vol 8 (11) ◽  
Author(s):  
Michael Gnant
Keyword(s):  
Breast Cancer ◽  
Bone Mineral Density ◽  
Vitamin D ◽  
Bone Loss ◽  
Bisphosphonate Treatment ◽  
Breast Cancer Patients ◽  
Adjuvant Setting ◽  
Mineral Density ◽  
Prevention Of Osteoporosis

Endocrine adjuvant therapy for breast cancer has been associated with a decrease in bone mineral density (BMD) and bone loss. For aromatase inhibitors, this bone loss is likely to be the most significant limitation to their long-term use. Treatments traditionally used to counteract his effect include exercise and supplementation with calcium and vitamin D. A newer treatment is the use of bisphosphonates, a class of drugs that reduce osteoclast activity. Clinical trials currently underway to examine the effect of bisphosphonate treatment on breast cancer patients have shown improvement in bone strength. Additional benefits of bisphosphonates, currently under study, give this class of drugs an important role to play in the treatment of cancer treatment-induced bone loss.

Sign in / Sign up

Export Citation Format

Share Document